Identification of amino acids in the N-terminal domain of corticotropin- releasing factor receptor 1 that are important determinants of high-affinity ligand binding

Journal of Neurochemistry

Volumn 72, Issue 1, 1999, Pages 388-395

  Wille, Sandra ^a   Sydow, Sabine ^a   Palchaudhuri, Monika R ^a   Spiess, Joachim ^a   Dautzenberg, Frank M ^a,b  

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Corticotropin releasing factor binding site; Corticotropin releasing factor receptor 1 mutagenesis; Cyclic AMP; Ligand binding

Indexed keywords

COMPLEMENTARY DNA; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CYCLIC AMP; IODINE 125;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CORTICOTROPIN RELEASE; GENE MUTATION; HUMAN; HUMAN CELL; LIGAND BINDING; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; RECEPTOR BINDING;

AMINO ACIDS; ANIMALS; BINDING SITES; CELLS, CULTURED; CORTICOTROPIN-RELEASING HORMONE; CYCLIC AMP; DNA, COMPLEMENTARY; HUMANS; KIDNEY; LIGANDS; MOLECULAR SEQUENCE DATA; MUTAGENESIS; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; RATS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SEQUENCE HOMOLOGY, AMINO ACID; TRANSFECTION;

ANIMALIA;

EID: 0032900285     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1999.0720388.x     Document Type: Article

References (59)

1. Bot G., Blake A. D., Li S., and Reisine T. (1998) Mutagenesis of a single amino acid in the rat μ-opioid receptor discriminates ligand binding. J. Neurochem. 70, 358-365.
2. Chang C. P., Pearse R. V. II, O'Connel S., and Rosenfeld M. G. (1993) Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron 11, 1187-1195.
3. Chen C. and Okayama H. (1987) High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7, 2745-2752.
4. Chen R., Lewis K. A., Perrin M. H., and Vale W. W. (1993) Expression cloning of a human corticotropin-releasing-factor receptor. Proc. Natl. Acad. Sci. USA 90, 8967-8971.
5. Couvineau A., Gaudin P., Maoret J. J., Rouyer-Fessard C., Nicole P., and Laburthe M. (1995) Highly conserved aspartate 68, tryptophan 73 and glycine 109 in the N-terminal extracellular domain of the human VIP receptor are essential for its ability to bind VIP. Biochem. Biophys. Res. Commun. 206, 246-252.
6. 1 receptor: three nonadjacent amino acids are responsible for species selectivity with respect to recognition of peptide histidine isoleucineamide. J. Biol. Chem. 271, 12795-12800.
7. Dautzenberg F. M., Dietrich K., Palchaudhuri M. R., and Spiess J. (1997) Identification of two corticotropin-releasing factor receptors from Xenopus laevis with high ligand selectivity: unusual pharmacology of the type I receptor. J. Neurochem. 69, 1640-1649.
8. Dautzenberg F. M., Wille S., Lohmann R., and Spiess J. (1998) Mapping of the ligand-selective domain of the Xenopus laevis corticotropin-releasing factor receptor 1: implications for the ligand-binding site. Proc. Natl. Acad. Sci. USA 95, 4941-4945.
9. Dixon R. A., Sigal I. S., Rands E., Register R. B., Candelore M. R., Blake A. D., and Strader C. D. (1987) Ligand binding to the β-adrenergic receptor involves its rhodopsin-like core. Nature 326, 73-77.
10. Donaldson C., Sutton S., Perrin M. H., Corrigan A. Z., Lewis K. A., Rivier J., Vaughan J. M., and Vale W. W. (1996) Cloning and characterization of human urocortin. Endocrinology 137, 2167-2170.
11. Dunn A. J. and Berridge C. W. (1990) Physiological and behavioral responses of corticotropin releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res. Rev. 15, 71-100.
12. Fong T. M., Huang R. R. C., and Strader C. D. (1992) Localization of agonist and antagonist binding domains of the human neurokinin-1 receptor. J. Biol. Chem. 267, 25664-25667.
13. Gaudin P., Couvineau A., Maoret J. J., Rouyer-Fessard C., and Laburthe M. (1995) Mutational analysis of cysteine residues within the extracellular domains of the human vasoactive intestinal peptide (VIP) 1 receptor identifies seven mutants that are defective in VIP binding. Biochem. Biophys. Res. Commun. 211, 901-908.
14. Gayle R. B. III, Sleath P. R., Srinivason S., Birks C. W., Weerawarna K. S., Cerretti D. P., Kozlosky C. J., Nelson N., Vanden Bos T., and Beckmann M. P. (1993) Importance of the amino terminus of the interleukin-8 receptor in ligand interactions. J. Biol. Chem. 268, 7283-7289.
15. Gourlet P., Vilardaga J. P., de Neef P., Waelbroeck M., Vandermeers A., and Robberecht P. (1996) The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors. Peptides 17, 825-829.
16. Greenwood M. T., Hukovic N., Kumar U., Panetta R., Hjorth S., Srikant C. B., and Patel Y. C. (1997) Ligand binding pocket of the human somatostatin receptor 5: mutational analysis of the extracellular domains. Mol. Pharmacol. 52, 807-814.
17. Gulyas J., Rivier C., Perrin M., Koerber C., Sutton S., Corrigan A., Lahrichi S. L., Craig W., Vale W., and Rivier J. (1995) Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Proc. Natl. Acad. Sci. USA 92, 10575-10579.
18. Hashimoto H., Ogawa N., Hagihara N., Yamamoto K., Imanishi K., Nogi H., Nishino A., Fujita T., Matsuda T., Nagata S., and Baba A. (1997) Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation. Mol. Pharmacol. 52, 128-135.
19. 8] vasotocin receptor. Proc. Natl. Acad. Sci. USA 93, 6907-6912.
20. 1, receptor. J. Biol. Chem. 269, 30953-30959.
21. Holtmann M. H., Hadac E. M., and Miller L. J. (1995) Critical contributions of amino-terminal extracellular domains in agonist binding and activation of secretin and vasoactive intestinal polypeptide receptors. J. Biol. Chem. 270, 14394-14398.
22. Holtmann M. H., Ganguli S., Hadac E. M., Dolu V., and Miller L. J. (1996) Multiple extracellular loop domains contribute critical determinants for agonist binding and activation of the secretin receptor. J. Biol. Chem. 271, 14944-14949.
23. Horn F., Weare J., Beukers M. W., Horsch S., Bairoch A., Chen W., Edvardsen O., Campagne F., and Vriend G. (1998) GPCRDB: an information system for G protein-coupled receptors. Nucleic Acids Res. 26, 275-279.
24. Huang R. R. C., Yu H., Strader C. D., and Fong T. M. (1994a) Interaction of substance P with the second and seventh transmembrane domains of the neurokinin-1 receptor. Biochemistry 33, 3007-3013.
25. Huang R. R. C., Yu H., Strader C. D., and Fong T. M. (1994e) Localization of the ligand binding site of the neurokinin-1 receptor: interpretation of chimeric mutations and single-residue substitutions. Mol. Pharmacol. 45, 690-695.
26. Ishihara T., Nakamura S., Kaziro Y., Takahashi T., Takahashi K., and Nagata S. (1991) Molecular cloning and expression of a cDNA encoding the secretin receptor. EMBO J. 10, 1635-1641.
27. Ishihara T., Shigemoto R., Mori K., Takahashi K., and Nagata S. (1992) Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 8, 811-819.
28. Kash K., Berthold M., Kahl U., Nordvall G., and Bartfai T. (1996) Delineation of the peptide binding site of the human galanin receptor. EMBO J. 15, 236-244.
29. Kishimoto T., Pearse R. V. II. Lin C. R., and Rosenfeld M. G. (1995) A sauvagine/corticotropin-releasing factor receptor expressed in heart and skeletal muscle. Proc. Natl. Acad. Sci. USA 92, 1108-1112.
30. Lee C. W., Luck M. D., Jüppner H., Potts J. T. Jr., Kronenberg H. M., and Gardella T. J. (1995) Homolog-scanning mutagenesis of the parathyroid hormone (PTH) receptor PTH-(1-34) binding determinants in the third extracellular loop. Mol. Endocrinol. 9, 1269-1278.
31. Liaw C. W., Lovenberg T. W., Barry G., Oltersdorf T., Grigoriadis D. E., and De Souza E. B. (1996) Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid. Endocrinology 137, 72-77.
32. Liaw C. W., Grigoriadis D. E., Lovenberg T. W., De Souza E. B., and Maki R. A. (1997a) Localization of ligand-binding domains of human corticotropin-releasing factor receptor: a chimeric receptor approach. Mol. Endocrinol. 11, 980-985.
33. Liaw C. W., Grigoriadis D. E., Lorang M. T., De Souza E. B., and Maki R. A. (1997b) Localization of agonist- and antagonist-binding domains of human corticotropin releasing factor receptors. Mol. Endocrinol. 11, 2048-2053.
34. Lovenberg T. W., Liaw C. W., Grigoriadis D. E., Clevenger W., Chalmers D. T., De Souza E. B., and Oltersdorf T. (1995) Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc. Natl. Acad. Sci. USA 92, 836-840.
35. Maguire M. E., van Arsdale P. M., and Gilman A. G. (1976) An agonist-specific effect of guanine-nucleotides on binding to the beta adrenergic receptor. Mol. Pharmacol. 12, 335-339.
36. Mayo K. E. (1992) Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol. Endocrinol. 6, 1734-1744.
37. Meng F., Taylor L. P., Hoversten M. T., Ueda Y., Ardati A., Reinscheid R. K., Monsma F. J., Watson S. J., Civelli O., and Akil H. (1996) Moving from the orphanin FQ receptor to an opioid receptor using four point mutations. J. Biol. Chem. 271, 32016-32020.
38. Montecucchi P. C. and Henshen A. (1981) Amino acid composition and sequence analysis of sauvagine, a new active peptide from the skin of Phyllomedusa sauvagei. Int. J. Peptide Protein Res. 18, 113-120.
39. Munson P. J. and Rodbard D. (1980) Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 107, 220-239.
40. Nehring R., Meyerhof W., and Richter D. (1995) Aspartic residue 124 in the third transmembrane domain of the somatostatin receptor subtype 3 is essential for somatostatin-14 binding. DNA Cell Biol. 14, 939-944.
41. Nicole P., Du K., Couvineau A., and Laburthe M. (1998) Site-directed mutagenesis of human vasoactive intestinal peptide receptor subtypes VIP1 and VIP2: evidence for difference in the structure-function relationship. J. Pharmacol. Exp. Ther. 284, 744-750.
42. Owens M. J. and Nemeroff C. B. (1991) Physiology and pharmacology of corticotropin releasing factor. Pharmacol. Rev. 43, 425-473.
43. Perrin M. H., Donaldson C. J., Chen R., Lewis K. A., and Vale W. W. (1993) Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor. Endocrinology 133, 3058-3061.
44. Perrin M., Donaldson C., Chen R., Blunt A., Berggren T., Bilezikjian L., Sawchenko P., and Vale W. (1995) Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc. Natl7. Acad. Sci. USA 92, 2969-2973.
45. Perrin M. H., Sutton S., Bain D., Berggren W. T., and Vale W. W. (1998) The first extracellular domain of corticotropin-releasing factor-R1 contains major binding determinants for urocortin and astressin. Endocrinology 139, 566-570.
46. Qi L. J., Leung A. T., Xiong Y., Marx K. A., and Abou-Samra A. B. (1997) Extracellular cysteines of the corticotropin-releasing factor receptor are critical for ligand interaction. Biochemistry 36, 12442-12448.
47. Ross P. C., Kostas C. M., and Ramabhadran T. V. (1994) A variant of the human corticotropin-releasing factor (CRF) receptor: cloning, expression and pharmacology. Biochem. Biophys. Res. Commun. 205, 1836-1842.
48. Sambrook J., Fritsch E. F., and Maniatis T. (1989) Molecular Cloning: A Laboratory Manual, 2nd edit., pp. 16.33-16.36. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
49. Stenzel P., Kesterson R., Yeung W., Cone R. D., Rittenberg M. B., and Stenzel-Poore M. P. (1995) Identification of a novel murine receptor for corticotropin-releasing hormone expressed in the heart. Mol. Endocrinol. 9, 637-645.
50. Strader C. D., Sigal I. S., and Dixon R. A. F. (1989) Structural basis of β-adrenergic receptor function. FASEB J. 3, 1825-1832.
51. Svoboda M., Tastenoy M., Van Rampelbergh J., Goossens J. F., De Neef P., Waelbroeck M., and Robberecht P. (1994) Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts. Biochem. Biophys. Res. Commun. 205, 1617-1624.
52. Sydow S., Radulovic J., Dautzenberg F. M., and Spiess J. (1997) Structure-function relationship of different domains of the rat corticotropin-releasing factor receptor. Brain Res. Mol. Brain Res. 52, 182-193.
53. Unson C. G., Cypess A. M., Kim H. N., Goldsmith P. K., Carruthers C. J. L., Merrifield R. B., and Sakmar T. P. (1995) Characterization of deletion and truncation mutants of the rat glucagon receptor. J. Biol. Chem. 270, 27720-27727.
54. Valdenaire O., Giller T., Breu V., Gottowick J., and Kilpatrick G. (1997) A new functional isoform of the human CRF2 receptor for corticotropin-releasing factor. Biochim. Biophys. Acta 1352, 129-132.
55. Vale W., Spiess J., Rivier C., and Rivier J. (1981) Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science 213, 1394-1397.
56. Vaughan J., Donaldson C., Bittencourt J., Perrin M. H., Lewis K., Sutton S., Chan R., Turnbull A. V., Lovejoy D., Rivier C., Rivier J., Sawchenko P. E., and Vale W. (1995) Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378, 287-292.
57. Vita N., Laurent P., Lefort S., Chalon P., Lelias J. M., Kaghad M., Le Fur G., Caput D., and Ferrara P. (1993) Primary structure and functional expression of mouse and human brain corticotropin releasing factor receptors. FEBS Lett. 335, 1-5.
58. Wheatley M., Hulme E. C., Birdsall N. J. M., Curtis C. A. M., Eveleigh P., Pedder E. K., and Poyner D. (1988) Peptide mapping studies on muscarinic receptors: receptor structure and location of the ligand binding site. Trends Pharmacol. Sci. 9 (Suppl.), 19-24.
59. Yu J., Xie L. Y., and Abou-Samra A. B. (1996) Molecular cloning of a type A chicken corticotropin-releasing factor receptor with high affinity for urotensin I. Endocrinology 137, 192-197.